United Therapeutics logo

United Therapeutics Income Statement

Revenue, expenses, and profitability over time

United Therapeutics generated $3.2B in trailing twelve-month revenue, up 0.1% year-over-year. Net income was $1.3B with a 40.61% net margin. Gross margin stands at 86.58% and operating margin at 45.29%. Diluted EPS is $27.05, which grew 0.1% year-over-year. Based on the Q1 2026 filing.

Latest FilingQ1 2026
Report Date2026-05-06
Market Cap$24.1B
P/E Ratio18.69
ROE20.26%

Tax

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income tax expense$95.2M$101.3M$98.9M$99.3M$79.7M$43.4M

Net Income

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net income$301.3M$322.2M$309.5M$338.7M$364.3M$274.9M

Revenue

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Total revenue$735.9M$794.4M$798.6M$799.5M$790.2M$781.5M